Autres langues Finch Therapeutics Group, Inc.

Actions

FNCHQ

US31773D2009

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:05:25 03/09/2026			Varia. 5j.	Varia. 1 janv.
10,35 ^USD	0,00%		0,00%	-23,26%

27/04	Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics et AstraZeneca annoncent des mises à jour cliniques sur les infections à Clostridium Difficile	CI
26/03	Approbation de la demande de gestion conjointe pour Finch Therapeutics Group, Inc.	CI

Autres langues

03/09	Second Modified First Amended Combined Joint Liquidation Plan and Disclosure Stataement Approved for Finch Therapeutics Group, Inc.
24/07	First Amended Disclosure Statement Conditionally Approved on an Interim Basis for Finch Therapeutics Group, Inc.
22/07	First Motion for Exclusivity Period Extension Approved For Finch Therapeutics Group, Inc.
22/07	First Amended Combined Joint Liquidation Plan and Disclosure Statement Filed by Finch Therapeutics Group, Inc.
20/07	Notice of Asset Purchase Agreement Filed by Finch Therapeutics Group, Inc.
07/07	First Motion for Exclusivity Period Extension Filed by Finch Therapeutics Group, Inc.
06/07	Combined Joint Liquidation Plan and Disclosure Statement Filed by Finch Therapeutics Group, Inc.
27/04	Acurx Pharmaceuticals, Inc., Adiso Therapeutics, Inc., Summit Therapeutics Inc., Finch Therapeutics Group, Inc. and Astrazeneca plc Announces Clostridium Difficile Infections Clinical Trial Updates
26/03	Motion for Joint Administration Approved for Finch Therapeutics Group, Inc.
23/03	Motion for Asset Sale Filed by Finch Therapeutics Group, Inc.
22/03	Motion for Joint Administration Filed by Finch Therapeutics Group, Inc.
22/03	Finch Therapeutics Group, Inc. Filed for Bankruptcy
08/12	Pepgen Inc. Appoints Joseph Vittiglio as Chief Business and Legal Officer, Effective December 8, 2025
21/10/24	Finch Announces Delisting from Nasdaq and SEC Deregistration
15/08/24	Ferring v Finch: Ripples From The Decision
13/08/24	Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
30/05/24	Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from S&P TMI Index
27/05/24	Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index
10/05/24	Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
25/03/24	Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
25/03/24	Finch Therapeutics Group, Inc. Auditor Raises 'Going Concern' Doubt
12/03/24	Top Premarket Decliners
08/11/23	Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
27/10/23	Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
10/08/23	Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023